Kiromic BioPharma logo

Kiromic BioPharma(OTC) KRBP

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-100%
1 Year-98%
1 Month+9,900%
N/A
Kiromic BioPharma last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-15
Kiromic BioPharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-10-07
1 month+9,900%USD 0.002026-09-11
3 month+0%USD 0.002026-07-15
Year to date+9,900%USD 0.002025-12-30
1 year-98%USD 0.012025-10-13
3 year-99.94%USD 0.182023-10-16
5 year-100%USD 59.102021-10-15
Since inception-100%USD 345.002020-10-16

Kiromic BioPharma Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$26.99M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Feb 14, 2025

KRBP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kiromic BioPharma

Kiromic BioPharma, Inc. is a biotechnology company focused on developing innovative allogeneic cell therapies using artificial intelligence. The company aims to create multi-indication T-cell treatments specifically designed to target solid tumors through the unique properties of Gamma Delta T cells.

Products and Services
  • ALEXIS-ISO-1: Allogeneic gamma delta CAR-T cell therapy targeting Isomesothelin
  • ALEXIS-PRO-1: Allogeneic gamma delta chimeric T cell therapy addressing PD-L1
  • Collaborative research and development partnerships to enhance therapeutic offerings
Growth Outlook
  • Strong focus on advancing proprietary therapies in a growing biotechnology market
  • Strategic partnerships with institutions to bolster research capabilities
  • Potential for significant market impact with successful therapy development
Financial Highlights
  • Recent quarterly net income of -$6.49 million, reflecting ongoing R&D investments
  • Cash and cash equivalents of $1.14 million as of Q4 2024, supporting operational needs
  • Trailing twelve months (TTM) revenue of $0, indicating a focus on development rather than sales
Kiromic BioPharma, Inc. operates in a highly specialized sector, leveraging advanced technology to develop therapies that could address significant unmet medical needs. The company's commitment to research and development is evident in its financials, with substantial investments aimed at bringing innovative treatments to market. Despite reporting no revenue, the strategic partnerships and focus on proprietary therapies position the company for potential growth in the evolving biotechnology landscape. Investors may find interest in the company's unique approach to cancer treatment and its potential for future advancements.
AI Generated • Sep 28, 2026

Industry

Biotechnology

Sector

Health Care

Employees

44

CEO

Pietro Bersani, CPA

Website

www.kiromic.com

Headquarters

Houston, TX 77054, US

KRBP Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

247.82%

Return on Capital

-1200.10%

Return on Assets

-314.78%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$1.11M

Operating Income

-$23.77M

EBITDA

-$20.94M

Operating Cash Flow

-$19.46M

Capital Expenditure

-$366.00K

Free Cash Flow

-$19.82M

Cash & ST Invst.

$1.14M

Total Debt

$14.57M

Kiromic BioPharma Performance Analysis

Kiromic BioPharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
Kiromic BioPharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-03-31N/A
Q22024-06-30N/A
Q32024-09-30N/A
Q42024-12-31N/A
Kiromic BioPharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -67.82N/A
20222022-12-31USD -1,932.642749.6%
20232023-12-31USD -21.41-98.9%
20242024-12-31USD -23.097.9%
Kiromic BioPharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-03-31-10.3%
Q22024-06-302.5%
Q32024-09-3093.2%
Q42024-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

44

N/A

Net Income

-$6.49M

-38.4%

EBITDA

-$5.16M

-47.2%

Quarterly Fundamentals

Name
Q4 2024YOY CHG

Total Cash

$1.14M

-64.5%

Total Debt

$14.57M

-6.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$228.00K

-75.0%

Short Term Debt

$14.34M

-2.0%

Return on Assets

-3.15%

N/A

Return on Invested Capital

1.92%

N/A

Free Cash Flow

-$3.68M

+33.4%

Operating Cash Flow

-$3.65M

+32.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HURATuHURA Biosciences, Inc.
$1.83+3.98%
CSTFCuraScientific Corp
$0.00+0.00%
LNDZFEvome Medical Technologies Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$12.01-7.12%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.32-2.71%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$43.64+2.63%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$107.35-2.89%

Questions About KRBP

What is the current price of Kiromic BioPharma?

Kiromic BioPharma is trading at N/A per share.

What is the 52-week range for Kiromic BioPharma?

Over the past 52 weeks, Kiromic BioPharma has traded between N/A and N/A.

How much debt does Kiromic BioPharma have?

As of the most recent reporting period, Kiromic BioPharma reported total debt of $14.57M.

How much cash does Kiromic BioPharma have on hand?

Kiromic BioPharma reported $1.80M in cash and cash equivalents in its most recent financial results.

What is Kiromic BioPharma’s dividend yield?

Kiromic BioPharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services